Article
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
Clinical lung cancer - 1 May 2020
Xia Hui, Xue Xingyang, Ding Huaxin, Ou Qiuxiang, Wu Xue, Nagasaka Misako, Shao Yang W, Hu Xingsheng, Ou Sai-Hong Ignatius
Abstract excerpt
BACKGROUND: Neurotrophin receptor kinase (NTRK) gene fusions (NTRK+) are rare but actionable oncogenic drivers present in a wide variety of solid tumors. However, the clinicopathologic characteristics of NTRK1 fusion-positive non-small-cell lung cancer are largely unknown. MATERIALS AND METHODS: Lung cancer tissue specimens and/or circulating cell-free DNA from patients with lung cancer who had undergone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.